Eversept Partners’s Sarepta Therapeutics SRPT Stock Holding History

Eversept Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-138,644	Closed	-$23.6M	–	97
2020 Q4	$23.6M	Buy	138,644 +136,747	+7,209%	+$20.3M	2.77%	15
2020 Q3	$266K	Sell	1,897 -69,834	-97%	-$10.6M	0.06%	47
2020 Q2	$11.5M	Buy	+71,731	New	+$9.76M	1.58%	19
2020 Q1	–	Sell	-75,000	Closed	-$9.68M	–	77
2019 Q4	$9.68M	Buy	+75,000	New	+$7.57M	1.71%	17
2019 Q3	–	Sell	-16,554	Closed	-$2.52M	–	65
2019 Q2	$2.52M	Sell	16,554 -67,020	-80%	-$8.15M	0.7%	32
2019 Q1	$9.96M	Buy	83,574 +43,080	+106%	+$5.54M	2.91%	11
2018 Q4	$4.42M	Sell	40,494 -1,700	-4%	-$213K	2.39%	11
2018 Q3	$6.81M	Buy	42,194 +2,194	+5%	+$300K	2.99%	12
2018 Q2	$5.29M	Buy	+40,000	New	+$3.77M	2.42%	17

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Eversept Partners's SRPT Position: Q1 2021 in Review

Eversept Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 138,644 shares — an estimated $23.6M sold.

Eversept Partners first reported a position in SRPT in Q2 2018 and held it in 9 quarters. The position peaked at $23.6M in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Eversept Partners reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Eversept Partners sold 138,644 Sarepta Therapeutics shares in Q1 2021, an estimated $23.6M.
Eversept Partners first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 9 quarters.
Eversept Partners's Sarepta Therapeutics position peaked at $23.6M in Q4 2020.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.